Announcements Trials
Browse Landscape

Phase

Phase NA 9Phase 1 4Phase 3 3Phase 2 3Phase EARLY_PHASE1 2Phase 2/3 2Phase 1/2 2

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 40Neoplasms 36Prostatic Neoplasms 32Colorectal Neoplasms 22Carcinoma, Non-Small-Cell Lung 22Leukemia, Myeloid, Acute 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasm Metastasis 14Polycystic Ovary Syndrome 13Lung Neoplasms 13Stomach Neoplasms 12Multiple Myeloma 11Carcinoma, Hepatocellular 11Recurrence 10Pancreatic Neoplasms 10Urinary Bladder Neoplasms 9Lymphoma 9Leukemia 9Myelodysplastic Syndromes 8Motor Activity 8Head and Neck Neoplasms 8Liver Neoplasms 7Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Esophageal Neoplasms 7Colonic Neoplasms 7Brain Neoplasms 7Pain 6Ovarian Neoplasms 6Lymphoma, Non-Hodgkin 6Lymphoma, Follicular 6

Interventions

valrubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × Completed × Carcinoma in Situ × Clear all
NCT00406068 2016-07-28

Mycobacterial Cell Wall-DNA Complex in Treatment of BCG-refractory Patients With Non-muscle Invasive Bladder Cancer

Bioniche Life Sciences Inc.

Phase 2/3 Completed
129 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Mycobacterium Infections, Neoplasm Recurrence, Local

NCT01316874 2015-06-12

Bladder Cancer

Endo Pharmaceuticals

Phase 2/3 Completed
90 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

Data powered by HemOnc (CC BY 4.0) Colophon âš¡